

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 81600

Title: Potent BET Inhibitor JAB-8263 Suppresses MYC Expression and Exerts Anti-tumor Activity in Colorectal Cancer Models

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06110600

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Greece

Author's Country/Territory: China

Manuscript submission date: 2022-11-20

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-24 00:37

Reviewer performed review: 2022-12-08 11:39

Review time: 14 Days and 11 Hours

| | |
|----------------------------|--|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Judgment by peer reviewers | Does this manuscript meet the code of ethics standards? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Does this manuscript have important novelty? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Does this manuscript have important creativity or innovation? |

| | |
|---------------------------------|---|
| | <input type="checkbox"/> [J31] Yes <input type="checkbox"/> [J30] No Does this manuscript use reliable research methods? <input type="checkbox"/> [J41] Yes <input type="checkbox"/> [J40] No Are the manuscript-accompanying data and figures authentic? <input type="checkbox"/> [J51] Yes <input type="checkbox"/> [J50] No Does this manuscript make scientifically significant conclusions? <input type="checkbox"/> [J61] Yes <input type="checkbox"/> [J60] No |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

In this manuscript, the authors report that the BET Inhibitor JAB-8263 exerts anti-tumor activity in CRC model. They concluded that BET can be a potential effective drug target for suppressing CRC growth, and BET inhibitor JAB-8263 can effectively suppress c-MYC expression. The methods are clearly described and results are reasonable. This study is really useful for readers interested in discovering the potential drug target of CRC. However, the following points need to be addressed. Minor comments: 1. There are some typing errors. 2. The limitations of this study need to be mentioned and discussed. 3 The reference type needs to be revised according to journal guideline.

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 81600

Title: Potent BET Inhibitor JAB-8263 Suppresses MYC Expression and Exerts Anti-tumor Activity in Colorectal Cancer Models

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06110640

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Australia

Author's Country/Territory: China

Manuscript submission date: 2022-11-20

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-24 00:37

Reviewer performed review: 2022-12-08 11:40

Review time: 14 Days and 11 Hours

| | |
|----------------------------|--|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Judgment by peer reviewers | Does this manuscript meet the code of ethics standards? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Does this manuscript have important novelty? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Does this manuscript have important creativity or innovation? |

| | |
|---------------------------------|---|
| | <input type="checkbox"/> [J31] Yes <input type="checkbox"/> [J30] No Does this manuscript use reliable research methods? <input type="checkbox"/> [J41] Yes <input type="checkbox"/> [J40] No Are the manuscript-accompanying data and figures authentic? <input type="checkbox"/> [J51] Yes <input type="checkbox"/> [J50] No Does this manuscript make scientifically significant conclusions? <input type="checkbox"/> [J61] Yes <input type="checkbox"/> [J60] No |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

The manuscript "Potent BET Inhibitor JAB-8263 Suppresses MYC Expression and Exerts Anti-tumor Activity in Colorectal Cancer Models" submitted by Liu et al., in my opinion, it is a well-written and interesting paper, and within the scope of WJGO. The authors investigated the inhibitory effect and mechanism of BET inhibitor JAB-8263 on CRC cells, and they concluded that JAB-8263 can effectively suppress c-MYC expression and exert anti-tumor activity in CRC models. This is an interesting and inspirational result. I recommend to accept this manuscript after a minor revision. Two suggestions: 1) About the research progress of BET inhibitor JAB-8263 in the Paragraph 3 of "Introduction" should be cited the related literature. 2) All images of Figure 1 should be more clear.